Pages that link to "Q44790692"
Jump to navigation
Jump to search
The following pages link to Efficacy of flupirtine on cognitive function in patients with CJD: A double-blind study (Q44790692):
Displaying 50 items.
- Safety and efficacy of quinacrine in human prion disease (PRION-1 study): a patient-preference trial (Q24653364) (← links)
- Diagnosis and evaluation of a patient with rapidly progressive dementia (Q26822666) (← links)
- Fatal prion disease in a mouse model of genetic E200K Creutzfeldt-Jakob disease (Q27348644) (← links)
- Systematic reviews in paediatric multiple sclerosis and Creutzfeldt-Jakob disease exemplify shortcomings in methods used to evaluate therapies in rare conditions (Q28075766) (← links)
- CSF concentrations of cAMP and cGMP are lower in patients with Creutzfeldt-Jakob disease but not Parkinson's disease and amyotrophic lateral sclerosis (Q28731571) (← links)
- The efficacy of tetracyclines in peripheral and intracerebral prion infection. (Q30496598) (← links)
- Efficacy of novel acridine derivatives in the inhibition of hPrP90-231 prion protein fragment toxicity (Q33560026) (← links)
- Redox control of prion and disease pathogenesis (Q33830151) (← links)
- Rapidly progressive Creutzfeldt-Jakob disease in patients with Familial Mediterranean Fever (Q33955559) (← links)
- Diphenylpyrazole-derived compounds increase survival time of mice after prion infection. (Q33957528) (← links)
- Successes and challenges in phenotype-based lead discovery for prion diseases (Q34104276) (← links)
- Quinacrine treatment trial for sporadic Creutzfeldt-Jakob disease (Q34415659) (← links)
- Experimental treatments for human transmissible spongiform encephalopathies: is there a role for pentosan polysulfate? (Q34625274) (← links)
- Flupirtine: pharmacology and clinical applications of a nonopioid analgesic and potentially neuroprotective compound. (Q34985534) (← links)
- Metabolic activation and analgesic effect of flupirtine in healthy subjects, influence of the polymorphic NAT2, UGT1A1 and GSTP1. (Q35135974) (← links)
- Molecular neurology of prion disease (Q35488760) (← links)
- Neuronal potassium channel openers in the management of epilepsy: role and potential of retigabine. (Q35683922) (← links)
- Rapidly progressive dementias and the treatment of human prion diseases (Q35832931) (← links)
- Prion diseases--close to effective therapy? (Q35906120) (← links)
- Recent advances in prion chemotherapeutics (Q38634199) (← links)
- Rational targeting for prion therapeutics. (Q35990277) (← links)
- Unexpected frequent hepatotoxicity of a prescription drug, flupirtine, marketed for about 30 years (Q36111238) (← links)
- Evidence for inhibitory effects of flupirtine, a centrally acting analgesic, on delayed rectifier k( ) currents in motor neuron-like cells. (Q36129188) (← links)
- A Single Subcutaneous Injection of Cellulose Ethers Administered Long before Infection Confers Sustained Protection against Prion Diseases in Rodents (Q36223572) (← links)
- Prion strain- and species-dependent effects of antiprion molecules in primary neuronal cultures (Q36315218) (← links)
- Novel aspects of prions, their receptor molecules, and innovative approaches for TSE therapy (Q36676179) (← links)
- Therapeutic approaches for prion disorders (Q36901944) (← links)
- Flupirtine as neuroprotective add-on therapy in autoimmune optic neuritis (Q36943102) (← links)
- A KCNQ channel opener for experimental neonatal seizures and status epilepticus (Q37151699) (← links)
- Prions: Beyond a Single Protein (Q37162363) (← links)
- Ethics in prion disease (Q37282279) (← links)
- Effect of flupirtine on the growth and viability of U373 malignant glioma cells. (Q37386230) (← links)
- Antibody-based immunotherapeutic attempts in experimental animal models of prion diseases (Q37514313) (← links)
- Therapeutic interventions ameliorating prion disease (Q37557690) (← links)
- Doxycycline in early CJD: a double-blinded randomised phase II and observational study. (Q37617090) (← links)
- Efficacy and mechanism of a glycoside compound inhibiting abnormal prion protein formation in prion-infected cells: implications of interferon and phosphodiesterase 4D-interacting protein (Q37713907) (← links)
- Gene expression profiling to identify druggable targets in prion diseases. (Q38028523) (← links)
- Melanin or a Melanin-Like Substance Interacts with the N-Terminal Portion of Prion Protein and Inhibits Abnormal Prion Protein Formation in Prion-Infected Cells (Q38721811) (← links)
- Structure-activity analysis and antiprion mechanism of isoprenoid compounds (Q38832872) (← links)
- Insights from Therapeutic Studies for PrP Prion Disease (Q39005891) (← links)
- Anti-prion activities and drug-like potential of functionalized quinacrine analogs with basic phenyl residues at the 9-amino position (Q39550752) (← links)
- Orally administered amyloidophilic compound is effective in prolonging the incubation periods of animals cerebrally infected with prion diseases in a prion strain-dependent manner (Q40078261) (← links)
- Protective effect of the KCNQ activator flupirtine on a model of repetitive febrile seizures (Q40315679) (← links)
- Toxicological Evaluation of Anti-Scrapie Trimethoxychalcones and Oxadiazoles (Q41069574) (← links)
- Orally administered indomethacin acutely reduces cellular prion protein in the small intestine and modestly increases survival of mice exposed to infectious prions (Q41535726) (← links)
- Clinical trials for prion disease: difficult challenges, but hope for the future (Q42576622) (← links)
- Atypical gating of M-type potassium channels conferred by mutations in uncharged residues in the S4 region of KCNQ2 causing benign familial neonatal convulsions. (Q42619127) (← links)
- Anti-prion activity found in beetle grub hemolymph of Trypoxylus dichotomus septentrionalis. (Q43277341) (← links)
- Doxycycline in Creutzfeldt-Jakob disease: a phase 2, randomised, double-blind, placebo-controlled trial. (Q43497178) (← links)
- Doxycycline for Creutzfeldt-Jakob disease: a failure, but a step in the right direction (Q45049023) (← links)